Positive results in Phase II trial of migaldendranib for DMO and nAMD
Ashvattha Therapeutics has announced positive results in the Phase II trial of migaldendranib (MGB), a targeted nanomedicine for the treatment of diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD).
The findings showed the annualised rate of IVT injections in all study eyes decreased from 8.4 to 1.6 per year, the annualised rate of fellow eyes decreased from 8.3 to 0.9, and improvements in BCVA and CST were also observed.
The multicentre, chronic dosing, 40-week Phase II clinical trial evaluated the safety and efficacy of subcutaneous MGB, an investigational VEGF receptor tyrosine kinase inhibitor covalently linked to a hydroxyl dendrimer, designed to shut down VEGF expression in activated macrophages and microglia, and hypoxic retinal pigment epithelial cells.
Previously anti-VEGF treated DMO and nAMD patients were enrolled. Responders to intravitreal (IVT) anti-VEGF were identified prior to entering the 40-week MGB treatment period. Criteria for supplemental anti-VEGF IVT while receiving subQ MGB during the study were pre-defined. The participants’ worse-seeing eye was designated as the study eye.
“These Phase II results demonstrate the potential of MGB to address one of the biggest challenges in retinal care today – the treatment burden associated with frequent in-office intravitreal injections,” said Susan Schneider, Acting Chief Medical Officer of Ashvattha Therapeutics. “With the safe systemic and ocular outcomes seen to date, MGB offers a differentiated approach that has the possibility to enable monthly at-home subcutaneous administration and could meaningfully reduce the burden of care for patients with DMO and nAMD, conditions that are chronic and typically bilateral.”
Unlike current anti-VEGF therapies that require repeated intravitreal injections directly into each affected eye, subcutaneously administered MGB provides a differentiated mechanism of action. It crosses the blood-retinal barrier in regions of inflammation and selectively normalises VEGF expression in activated macrophages and microglia, and hypoxic retinal pigment epithelial cells. By reducing VEGF expression rather than blocking VEGF signalling, MGB reduces the need for anti-VEGF intravitreal injections, which must be given in the doctor’s office, and should potentially improve patient compliance by a safe, at home, monthly administered product.
Bruno Quinney, Content Team, DDW
